JP2021529180A5 - - Google Patents

Info

Publication number
JP2021529180A5
JP2021529180A5 JP2020571817A JP2020571817A JP2021529180A5 JP 2021529180 A5 JP2021529180 A5 JP 2021529180A5 JP 2020571817 A JP2020571817 A JP 2020571817A JP 2020571817 A JP2020571817 A JP 2020571817A JP 2021529180 A5 JP2021529180 A5 JP 2021529180A5
Authority
JP
Japan
Prior art keywords
fragment
dna
active substance
derivative
biofilm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020571817A
Other languages
English (en)
Japanese (ja)
Other versions
JP7665337B2 (ja
JP2021529180A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040008 external-priority patent/WO2020006528A2/en
Publication of JP2021529180A publication Critical patent/JP2021529180A/ja
Publication of JP2021529180A5 publication Critical patent/JP2021529180A5/ja
Priority to JP2024113962A priority Critical patent/JP2024138001A/ja
Application granted granted Critical
Publication of JP7665337B2 publication Critical patent/JP7665337B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020571817A 2018-06-29 2019-06-28 Ｅｐｓを媒介するための組成物および方法 Active JP7665337B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024113962A JP2024138001A (ja) 2018-06-29 2024-07-17 Ｅｐｓを媒介するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692581P 2018-06-29 2018-06-29
US62/692,581 2018-06-29
PCT/US2019/040008 WO2020006528A2 (en) 2018-06-29 2019-06-28 Compositions and methods for mediating eps

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024113962A Division JP2024138001A (ja) 2018-06-29 2024-07-17 Ｅｐｓを媒介するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2021529180A JP2021529180A (ja) 2021-10-28
JP2021529180A5 true JP2021529180A5 (enExample) 2022-06-28
JP7665337B2 JP7665337B2 (ja) 2025-04-21

Family

ID=68985235

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571817A Active JP7665337B2 (ja) 2018-06-29 2019-06-28 Ｅｐｓを媒介するための組成物および方法
JP2024113962A Pending JP2024138001A (ja) 2018-06-29 2024-07-17 Ｅｐｓを媒介するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024113962A Pending JP2024138001A (ja) 2018-06-29 2024-07-17 Ｅｐｓを媒介するための組成物および方法

Country Status (12)

Country Link
US (1) US20210139610A1 (enExample)
EP (1) EP3813811A4 (enExample)
JP (2) JP7665337B2 (enExample)
KR (1) KR20210025075A (enExample)
CN (1) CN112672736A (enExample)
AU (2) AU2019291944B2 (enExample)
BR (1) BR112020026557A2 (enExample)
CA (1) CA3104140A1 (enExample)
IL (1) IL279459A (enExample)
MX (3) MX2020014006A (enExample)
SG (1) SG11202013060UA (enExample)
WO (1) WO2020006528A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170178A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
AU2019354829B2 (en) 2018-10-05 2025-04-17 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms
CA3183196A1 (en) * 2020-07-07 2022-01-13 Steven D. Goodman Combination therapies for the treatment and prevention of biofilms
US20220204600A1 (en) * 2020-12-30 2022-06-30 Trellis Bioscience, Inc. Therapeutic protein formulations comprising anti-dnabii antibodies and uses thereof
WO2022187274A1 (en) * 2021-03-01 2022-09-09 Carlo Ratti Combination therapy for treatment of conditions associated with aging
CN115304656B (zh) * 2022-06-22 2025-01-17 中国人民解放军海军军医大学第一附属医院 一种特异性激活细胞泛凋亡途径的囊泡药物构建及应用
CN118541144A (zh) * 2022-12-23 2024-08-23 中国医学科学院基础医学研究所 精胺在预防和治疗炎症性疾病中的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100390332B1 (ko) * 2000-08-02 2003-07-07 유원민 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
JP5670783B2 (ja) * 2011-03-07 2015-02-18 花王株式会社 バイオフィルムの除去方法
WO2012151555A1 (en) * 2011-05-04 2012-11-08 President And Fellows Of Harvard College Methods and coatings for treating biofilms
RU2694758C2 (ru) * 2012-12-20 2019-07-16 Раджив Бхушан Антимикробные композиции
EP2796876A1 (en) * 2013-04-25 2014-10-29 Hasenkam ApS Strip for monitoring analyte concentrations
AU2014268565B2 (en) 2013-05-22 2018-01-18 Curza Global, Llc Compositions and methods comprising a polyamine
US11013858B2 (en) * 2016-01-12 2021-05-25 David S. Goldsmith Nonjacketing side-entry connectors and prosthetic disorder response systems
US20150086561A1 (en) * 2013-09-26 2015-03-26 Trellis Bioscience, Llc Binding moieties for biofilm remediation
CA2941933A1 (en) 2014-03-13 2015-09-17 The Secretary Of State For Health Antimicrobial conjugates, method for production and uses thereof
SG11201707345VA (en) * 2015-03-12 2017-10-30 Micreos Human Health Bv Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
US9801909B2 (en) * 2015-04-06 2017-10-31 The Penn State Research Foundation Compositions and methods for combating bacterial infections by killing persister cells with mitomycin C
WO2017023863A1 (en) * 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
FR3055801B1 (fr) * 2016-09-15 2020-10-30 Virbac Derives esters de squalamine pour le traitement des infections
CA3058813A1 (en) * 2017-04-05 2018-10-11 University Of Utah Research Foundation Compositions and methods comprising a triaryl polyamine

Similar Documents

Publication Publication Date Title
JP2021529180A5 (enExample)
Perna et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance
JP5902141B2 (ja) 脂質キナーゼおよびｍＴＯＲのデュアル阻害剤としてのイミダゾキノリン
JP5520433B2 (ja) 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用
Gwisai et al. Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, hospital-acquired bacterial infections
Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
KR20180037228A (ko) 항박테리아 치료제 및 예방제
JP2012520883A5 (enExample)
US10064858B2 (en) Methods and compositions for treating bacterial infections with iron chelators
HK1200103A1 (en) Compositions and methods for treating vaginal infections and pathogenic vaginal biofilms
AU2003267079B2 (en) Factors that bind intestinal toxins
Panarsky et al. Anti-inflammatory effects of ladostigil and its metabolites in aged rat brain and in microglial cells
WO2017009373A1 (en) Histone deacetylase inhibition enhances antimicrobial peptide but not inflammatory cytokine expression upon bacterial challenge
CN113924288A (zh) 一种含喹啉基化合物、药物组合物以及其用途
D. Pranger et al. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach
JP6590924B2 (ja) 微生物感染を治療するための相乗的組成物
TW201021791A (en) Antimicrobial molecules for treating multi-drug resistant and extensively drug resistant strains of mycobacterium
Asif Antimicrobial and anti-tubercular activity of quinolone analogues
WO2023211684A2 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
RU2021101319A (ru) Составы и способы для воздействия на впв
CN114652715A (zh) 联合疗法
Holbert POLYAMINE OXIDATION-ASSOCIATED DAMAGE: FRIEND OR FOE? IMPLICATIONS FOR POLYAMINE THERAPEUTIC INTERVENTIONS
JP2013538868A5 (enExample)
CN103122368A (zh) 一种喹喔啉类化合物作为抗结核分枝杆菌抑制剂的应用
Nawrot Study of pyridine derivatives as potential antimycobacterial active drugs.